KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
European Commission approves Amgen's IMDYLLTRA for extensive-stage small cell lung cancer based on Phase III DeLLphi-304 trial demonstrating 40% reduction in mortality risk compared to chemotherapy.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
European Commission approval for small cell lung cancer, extensive stage based on Phase III DeLLphi-304 trial showing 40% reduction in mortality risk versus chemotherapy
Importance:8/10
Sentiment:
0.95
regulatory approvalEuropean Commissiononcologysmall cell lung cancerPhase 3mortality reduction
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on June 3, 2026 2:21 PM